project . 2020 - 2022 . On going

MANCO

Monoclonal Antibodies against 2019-New Coronavirus
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 101003651 Call for proposal: H2020-SC1-PHE-CORONAVIRUS-2020
  • Funded under: H2020 | RIA Overall Budget: 3,034,580 EURFunder Contribution: 3,034,580 EUR
  • Status: On going
  • Start Date
    01 Mar 2020
    End Date
    31 May 2022
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Lessons learned from, and intervention efforts against SARS coronavirus (CoV), MERS-CoV and other emerging viruses provide invaluable information to accelerate the coordinated response against 2019 novel (2019 -n)CoV and the rapid development and manufacture of new diagnostic, prophylactic and therapeutic intervention strategies. A -promising approach to both patient management of emerging viral infections and to better preparedness and response to emerging epidemics is the use of monoclonal antibodies. MANCO aims at contributing to the rapid international response against 2019-nCoV, through preclinical and clinical evaluation of monoclonal antibodies against 20...
Description
Lessons learned from, and intervention efforts against SARS coronavirus (CoV), MERS-CoV and other emerging viruses provide invaluable information to accelerate the coordinated response against 2019 novel (2019 -n)CoV and the rapid development and manufacture of new diagnostic, prophylactic and therapeutic intervention strategies. A -promising approach to both patient management of emerging viral infections and to better preparedness and response to emerging epidemics is the use of monoclonal antibodies. MANCO aims at contributing to the rapid international response against 2019-nCoV, through preclinical and clinical evaluation of monoclonal antibodies against 20...
Any information missing or wrong?Report an Issue